Loading...

Karyopharm Therapeutics Inc.

KPTINASDAQ
Healthcare
Biotechnology
$4.55
$-0.45(-9.00%)

Karyopharm Therapeutics Inc. KPTI Peers

See (KPTI) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
KPTI$4.55-9.00%38.1M-0.37-$11.87N/A
VRTX$468.85-2.23%120.4B-123.06-$3.81N/A
REGN$567.74+1.43%60.2B14.42$39.36+0.31%
SGEN$228.74-0.07%43.2B-57.19-$4.00N/A
ALNY$314.94-2.39%41B-149.91-$2.10N/A
ARGX$560.24-0.54%34.3B34.22$16.39N/A
BNTX$112.89-0.90%27.1B-30.03-$3.76N/A
BGNE$184.71+0.49%20.2B-22.55-$8.19N/A
RPRX$35.84-0.78%20.1B14.62$2.45+2.98%
DNA-WT$0.27-2.76%18.7BN/AN/AN/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

KPTI vs VRTX Comparison

KPTI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KPTI stands at 38.1M. In comparison, VRTX has a market cap of 120.4B. Regarding current trading prices, KPTI is priced at $4.55, while VRTX trades at $468.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KPTI currently has a P/E ratio of -0.37, whereas VRTX's P/E ratio is -123.06. In terms of profitability, KPTI's ROE is +0.37%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, KPTI is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for KPTI.

Stock Price Comparison

Loading...

Frequently Asked Questions

;